Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 13;15(1):e0227012.
doi: 10.1371/journal.pone.0227012. eCollection 2020.

Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study

Inki Moon  1 , Seo-Young Lee  1 , Hyung-Kwan Kim  1 , Kyung-Do Han  2 , Soongu Kwak  1 , Minkwan Kim  1 , Hyun-Jung Lee  1 , In-Chang Hwang  3 , Heesun Lee  4 , Jun-Bean Park  1 , Yeonyee E Yoon  3 , Yong-Jin Kim  1 , Goo-Yeong Cho  3
Affiliations

Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study

Inki Moon et al. PLoS One. .

Abstract

Temporal trends of the prevalence and incidence of hypertrophic cardiomyopathy (HCM) have not been well established in Asian populations. Using the Korean National Health Insurance Services database, we identified patients with a confirmed diagnosis of HCM between 2010 and 2016. The annual prevalence and incidence of HCM, and their clinical characteristics were investigated. The prevalence of HCM has increased from 0.016% (n = 6313) in 2010 to 0.031% (n = 13,035) in 2016. During a 7-year period, 13,229 patients were newly diagnosed with HCM. The incidence rate increased from 4.15 (per 100,000 person-years) in 2010 to 5.6 in 2016. The prevalence and incidence of HCM increased with age and peaked during the 70s, with male predominance in all age groups. Chest pain is the most frequent clinical presentation followed by shortness of breath and syncope. Hypertension and dyslipidemia were the two most common comorbidities. Heart failure and atrial fibrillation was diagnosed in about 1/3 and 1/4 of patients with HCM, respectively. The prevalence and incidence of HCM gradually increased from 2010 to 2016, possibly due to heightened recognition of the disease. Given the progressively high incidence of HCM with age and high prevalence of coexisting modifiable risk factors, continued efforts are required to increase awareness regarding HCM-related symptoms and potential complications.

PubMed Disclaimer

Conflict of interest statement

Prof. Hyung-Kwan Kim (HK-K) reports research grants from Actelion, GSK, Handok Pharm, Dae-Woong Pharm, Yuhan, Hanmi, ChongKunDang Pharm and Norvatis. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The remaining authors have nothing to disclose.

Figures

Fig 1
Fig 1. The prevalence of HCM from 2010 to 2016.
A. Temporal trend of the prevalence of HCM stratified by gender. B. Age-stratified temporal trend of HCM prevalence. HCM = hypertrophic cardiomyopathy.
Fig 2
Fig 2. The incidence of HCM from 2010 to 2016.
Temporal trend of the incidence rate of HCM stratified by gender. HCM = hypertrophic cardiomyopathy.
Fig 3
Fig 3. Age distribution of the newly-diagnosed HCM cohort by gender.
HCM = hypertrophic cardiomyopathy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. 10.1093/eurheartj/ehu284 - DOI - PubMed
    1. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783–831. 10.1161/CIR.0b013e318223e2bd - DOI - PubMed
    1. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83–99. 10.1016/j.jacc.2014.05.003 - DOI - PubMed
    1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785–9. 10.1161/01.cir.92.4.785 - DOI - PubMed
    1. Adabag AS, Kuskowski MA, Maron BJ. Determinants for clinical diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006;98(11):1507–11. 10.1016/j.amjcard.2006.07.029 - DOI - PubMed

Publication types

Grants and funding

Prof. Hyung-Kwan Kim (HK-K) reports research grants from Actelion, GSK, Handok Pharm, Dae-Woong Pharm, Yuhan, Hanmi, ChongKunDang Pharm and Norvatis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.